Difficulties in the oncology diagnosis with systemic sclerosis. Сase report
- Authors: Menshikova I.V.1, Sobyanina A.N.1, Prokofieva Y.A.1, Kolosova I.R.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 27, No 2 (2025): Neurology and Rheumatology
- Pages: 123-128
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/288845
- DOI: https://doi.org/10.26442/20751753.2025.2.203162
- ID: 288845
Cite item
Full Text
Abstract
Systemic sclerois (SS) is a relatively rare immunoinflammatory disease characterized by vasculopathy, immune abnormalities and generalized fibrosis. The prevalence of cancer in SS ranges from 3 to 11%, with tumors most commonly identified in the lung or gastrointestinal tract. Despite regular follow-up of patients with SS by rheumatologists, the oncologic process is often diagnosed at late stages. We describe the clinical observation of a 71-year-old patient with a long history of SS in whom the tumor process was detected at the stage of bone metastases, and morphological verification was difficult.
Full Text
##article.viewOnOriginalSite##About the authors
Irina V. Menshikova
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: ivmenshikova@mail.ru
ORCID iD: 0000-0003-3181-5272
D. Sci. (Med.), Prof.
Russian Federation, MoscowAnna N. Sobyanina
Sechenov First Moscow State Medical University (Sechenov University)
Email: ivmenshikova@mail.ru
ORCID iD: 0009-0000-4733-6263
Сlinical Resident
Russian Federation, MoscowYulia A. Prokofieva
Sechenov First Moscow State Medical University (Sechenov University)
Email: ivmenshikova@mail.ru
ORCID iD: 0000-0001-8658-3435
Assistant
Russian Federation, MoscowIrina R. Kolosova
Sechenov First Moscow State Medical University (Sechenov University)
Email: ivmenshikova@mail.ru
ORCID iD: 0000-0002-3924-6345
Cand. Sci. (Med.)
Russian Federation, MoscowReferences
- Потекаев Н.Н., Вавилов В.В. Патогенез склеродермии: современные представления. Клиническая дерматология и венерология. 2012;5:8-15 [Potekaev NN, Vavilov VV. Pathogenesis of scleroderma: Current ideas. Russian Journal of Clinical Dermatology and Venereology. 2012;10(5):8-15 (in Russian)].
- Шостак Н.А., Клименко А.А., Демидова Н.А., Андрияшкина Д.Ю. Склеродермия как паранеопластический синдром и опухоли, ассоциированные со склеродермией. Клиницист. 2020;14(1-2):55-61 [Shostak N.A., Klimenko A.A., Demidova N.A., Andriyashkina D.Yu. Scleroderma as a paraneoplastic syndrome and tumors associated with scleroderma. The Clinician. 2020;14(1-2):55-61 (in Russian)]. doi: 10.17650/1818-8338-2020-14-1-2-55-61
- Головач И.Ю., Егудина Е.Д. Склеродермоподобный паранеопластический синдром: ревматология "overlap" онкология. Лікар-практик. 2018;7(3):17-22 [Golovach IYu, Egudina ED. Sklerodermopodobnyi paraneoplasticheskii sindrom: revmatologiia “overlap” onkologiia. Líkar-praktik. 2018;7(3):17-22 (in Russian)].
- Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29-40. doi: 10.1136/ard-2024-226430
- Olesen AB, Sværke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol. 2010;163(4):800-6. doi: 10.1111/j.1365-2133.2010.09861.x
- Shah AA, Rosen A, Hummers L, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 2010;62(9):2787-95. doi: 10.1002/art.27549
- Moinzadeh P, Fonseca C, Hellmich M, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther. 2014;16:R53. doi: 10.1186/ar4486
- Chung L, Ferrari G, Ton Cet al. The risk of cancer development in systemic sclerosis: a meta-analysis. Cancer Epidemiol. 2013;37(3):321-6. doi: 10.1016/j.canep.2013.04.014
- Bernal-Bello D., Garcíade T., Guillén-del Castillo A. et al. Novel risk factors related to cancer in scleroderma. Autoimmunity Rev. 2017;16(5):461-8.
Supplementary files
